Who
Ron Bentsur
Chairman & CEO
Company insider
Files Form 4 as: Chairman & CEO, Nuvectis Pharma; Director, Beyond Air; Director, Stemline Therapeutics; Chief Executive Officer, Keryx Biopharmaceuticals; CEO, XTL Biopharmaceuticals.
In numbers
- Trades disclosed
- 221
- Buys
- 79
- Sells
- 53
- Bought
- $3.2M
- Sold
- $13.6M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 2 Jan 2006
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $250K12,500 at $20.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $250K12,500 at $20.00 | filing |
| 6 Jan 2026filed 9 Jan 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 6 Jan 2026filed 9 Jan 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 5 Nov 2025filed 6 Nov 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $29K5,000 at $5.72 | filing |
| 2 Jan 2025filed 3 Jan 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 24 Dec 2024filed 26 Dec 2024 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $21K4,500 at $4.65 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —45,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —45,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —40,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —40,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —30,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —25,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —25,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —25,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —25,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code D | —24,000 | filing |
| 22 Nov 2024filed 26 Nov 2024 | XAIR Beyond Airoption or derivative · Medical Devices | SEC FORM 4 Code A | —24,000 | filing |
| 15 Nov 2024filed 18 Nov 2024 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $98K20,000 at $4.92 | filing |
News
Nuvectis Pharma (NASDAQ:NVCT) Stock Falls 6.8% – Here's WhyNVCT · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Ron Bentsur; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.